93 Results

People

  1. Landgren
    Landgren
  2. Hultcrantz
    Hultcrantz
  3. Mailankody
    Mailankody
  4. Korde
    Korde
  5. Lesokhin
    Lesokhin
  6. Hassoun
    Hassoun
  7. Rustad
    Rustad
  8. Giralt
    Giralt
  9. Landau
    Landau
  10. Shah
    Shah

Groups

  1. Center for Hematologic Malignancies (93)
  2. Department of Medicine (93)
  3. Hematologic Malignancies Research (93)
  4. Hematologic Malignancies, Division of (93)
  5. Myeloma (93)
  6. Sloan Kettering Institute Postdocs (93)
  7. Survivorship Research (56)
  8. Epidemiology and Biostatistics (49)
  9. Bone Marrow Transplant (37)
  10. CTCR Scholars (37)
  1. "Hematologic Malignancies Research"
  2. "Carl Landgren"
  3. "Sloan Kettering Institute Postdocs"
Formats
  1. Meeting Abstract (54)
  2. Journal Article (30)
  3. Research Letter (5)
  4. Review (2)
  5. Book Section (1)
  6. Correspondence (1)
Groups
  1. Center for Hematologic Malignancies (93)
  2. Department of Medicine (93)
  3. Hematologic Malignancies Research (93)
  4. Hematologic Malignancies, Division of (93)
  5. Myeloma (93)
  6. Sloan Kettering Institute Postdocs (93)

More Groups

People
  1. Carl Landgren (93)
  2. Malin Hultcrantz (80)
  3. Sham Mailankody (53)
  4. Neha Korde (51)
  5. Alexander Lesokhin (44)
  6. Hani Hassoun (41)

More People

Years
  1. 2023 (2)
  2. 2022 (3)
  3. 2021 (10)
  4. 2020 (22)
  5. 2019 (24)
  6. 2018 (18)

More Years

Publications
  1. Blood (36)
  2. Clinical Lymphoma, Myeloma and Leukemia (9)
  3. Blood Cancer Journal (6)
  4. Journal of Clinical Oncology (5)
  5. JAMA Oncology (4)
  6. Haematologica (3)

More Publications

Publishers
  1. American Society of Hematology (38)
  2. Elsevier Inc. (11)
  3. Nature Publishing Group (9)
  4. American Society of Clinical Oncology (5)
  5. American Medical Association (4)
  6. Elsevier Science, Inc. (3)

More Publishers

Results (93)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A whole foods plant-based weight loss intervention improves quality of life, metabolic, microbiome and immune profile in MGUS/SMM as well as progression trajectory in a subset - the Nutrivention trial
    Meeting Abstract

    Shah, U. A.; Castro, F.; Derkach, A.; Fei, T.; Hosszu, K. K.; McAvoy, D.; DeWolf, S.; Cross, J.; Gradissimo, A.; Nwankwo, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Journal Article

    Tan, C. R.; Derkach, A.; Nemirovsky, D.; Ciardiello, A.; Diamond, B.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Maclachlan, K.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save
  • Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study
    Correspondence

    Mailankody, S.; Salcedo, M.; Tavitian, E.; Burge, M.; Korde, N.; Hassoun, H.; Lesokhin, A.; Lahoud, O.; Smith, E.; Hultcrantz, M.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • GPRC5D-targeted CAR T cells for myeloma
    Journal Article

    Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Nutrition perceptions, needs and practices among patients with plasma cell disorders
    Research Letter

    Malik, M. A.; Sweeney, N. W.; Jafri, M.; Derkach, A.; Chmielewski, C.; Adintori, P. A.; Mailankody, S.; Korde, N.; Tan, C. R.; Hassoun, H.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Using mobile wearables to establish sleep bioprofiles in newly diagnosed multiple myeloma (MM) patients
    Meeting Abstract

    Hevroni, G.; Mastey, D.; Tavitian, E.; Derkach, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Hultcrantz, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Providing nutritional guidance for patients with plasma cell disorders - A missed opportunity for hematologists and oncologists?
    Meeting Abstract

    Sweeney, N.; Malik, M.; Jafri, M.; Derkach, A.; Chmielewski, C.; Adintori, P.; Mailankody, S.; Korde, N.; Tan, C.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is impacted positively by stool butyrate and healthier plant forward diets
    Meeting Abstract

    Shah, U.; Derkach, A.; Adintori, P.; Cross, J.; Maclachlan, K.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Research Letter

    Korde, N.; Mastey, D.; Tavitian, E.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Shah, U.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save